Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Vaxart Inc

VXRT
Current price
0.61 USD -0.001 USD (-0.16%)
Last closed 0.61 USD
Company vaxart.com
ISIN US92243A2006
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 133 053 056 USD
Yield for 12 month +1.33 %
1Y
3Y
5Y
10Y
15Y
VXRT
21.11.2021 - 28.11.2021

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Address: 170 Harbor Way, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.83 USD

P/E ratio

Dividend Yield

Current Year

+7 379 000 USD

Last Year

+107 000 USD

Current Quarter

+4 933 000 USD

Last Quarter

+6 401 000 USD

Current Year

-60 763 000 USD

Last Year

-3 160 000 USD

Current Quarter

+4 933 000 USD

Last Quarter

-11 079 000 USD

Key Figures VXRT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -66 262 000 USD
Operating Margin TTM -253.96 %
PE Ratio
Return On Assets TTM -39.68 %
PEG Ratio
Return On Equity TTM -91.66 %
Wall Street Target Price 4.83 USD
Revenue TTM 13 928 000 USD
Book Value 0.38 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 371.40 %
Dividend Yield
Gross Profit TTM -80 947 000 USD
Earnings per share -0.40 USD
Diluted Eps TTM -0.40 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics VXRT

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History VXRT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date 09.11.2012
Forward Annual Dividend Yield
Last Split Factor 1:11
Payout Ratio
Last Split Date 14.02.2018
Dividend Date 14.02.2018

Stock Valuation VXRT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 42.735
Enterprise Value Revenue 4.6752
Price Sales TTM 9.5529
Enterprise Value EBITDA -0.1715
Price Book MRQ 1.9676

Financials VXRT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators VXRT

For 52 weeks

0.52 USD 1.54 USD
50 Day MA 0.70 USD
Shares Short Prior Month 11 460 312
200 Day MA 0.81 USD
Short Ratio 11.71
Shares Short 11 194 077
Short Percent 5.00 %